المؤلفون: Yang J; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Guo X; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Cui Z; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Guo H; Department of Orthopedics, Jincheng General Hospital, Jincheng, China., Dong JN; Department of Gynecology, Gaoping People's Hospital, Jincheng, China.

المصدر: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Sep 02; Vol. 15, pp. 1431676. Date of Electronic Publication: 2024 Sep 02 (Print Publication: 2024).

نوع المنشور: Systematic Review; Meta-Analysis; Journal Article; Comparative Study

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/therapeutic use , Denosumab*/administration & dosage , Osteoporosis, Postmenopausal*/drug therapy , Teriparatide*/administration & dosage , Teriparatide*/therapeutic use , Teriparatide*/adverse effects , Bone Density Conservation Agents*/administration & dosage , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects , Diphosphonates*/administration & dosage , Diphosphonates*/therapeutic use, Humans ; Female ; Administration, Oral ; Bone Density/drug effects ; Treatment Outcome

المؤلفون: Cosman F; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, United States., Oates M; Amgen Inc., Thousand Oaks, CA 91230, United States., Betah D; Amgen Inc., Thousand Oaks, CA 91230, United States., Timoshanko J; UCB Pharma, Slough SL1 3WE, United Kingdom., Wang Z; Amgen Inc., Thousand Oaks, CA 91230, United States., Ferrari S; Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland., McClung MR; Oregon Osteoporosis Center, Portland, OR 97225, United States.

المصدر: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2024 Sep 02; Vol. 39 (9), pp. 1268-1277.

نوع المنشور: Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study

بيانات الدورية: Publisher: American Society for Bone and Mineral Research Country of Publication: England NLM ID: 8610640 Publication Model: Print Cited Medium: Internet ISSN: 1523-4681 (Electronic) Linking ISSN: 08840431 NLM ISO Abbreviation: J Bone Miner Res Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/therapeutic use , Denosumab*/pharmacology , Bone Density*/drug effects, Humans ; Female ; Aged ; Middle Aged ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Fractures, Bone/epidemiology ; Bone Density Conservation Agents/therapeutic use ; Bone Density Conservation Agents/pharmacology

المؤلفون: Diab DL; College of Medicine, Cincinnati VA Medical Center, Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati, OH, USA., Watts NB; Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA.

المصدر: Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Sep; Vol. 23 (9), pp. 1069-1077. Date of Electronic Publication: 2024 Sep 11.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE

مواضيع طبية MeSH: Denosumab*/adverse effects , Denosumab*/administration & dosage , Osteoporosis*/chemically induced , Osteoporosis*/drug therapy , Bone Density Conservation Agents*/adverse effects , Bone Density Conservation Agents*/administration & dosage, Humans ; Female ; Bone Density/drug effects ; Male ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/pharmacology ; RANK Ligand/adverse effects ; RANK Ligand/antagonists & inhibitors ; RANK Ligand/administration & dosage ; Animals ; Diphosphonates/adverse effects ; Diphosphonates/administration & dosage ; Fractures, Bone/chemically induced ; Fractures, Bone/prevention & control

المؤلفون: Mineta K; Department of Orthopaedic Surgery, Tokushima Kensei Hospital, 4-9 Shimosuketo-cho, Tokushima 770-8547, Japan., Nishisho T; Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. Electronic address: tnishisho@tokushima-u.ac.jp., Okada M; Department of Orthopaedic Surgery, Tokushima Kensei Hospital, 4-9 Shimosuketo-cho, Tokushima 770-8547, Japan., Kamada M; Department of Orthopaedic Surgery, Tokushima Kensei Hospital, 4-9 Shimosuketo-cho, Tokushima 770-8547, Japan., Sairyo K; Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.

المصدر: Bone [Bone] 2024 Sep; Vol. 186, pp. 117164. Date of Electronic Publication: 2024 Jun 12.

نوع المنشور: Journal Article; Observational Study

بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 8504048 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2763 (Electronic) Linking ISSN: 18732763 NLM ISO Abbreviation: Bone Subsets: MEDLINE

مواضيع طبية MeSH: Osteoporosis*/drug therapy , Bone Density*/drug effects , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/adverse effects, Humans ; Female ; Male ; Aged ; Middle Aged ; Treatment Outcome ; Aged, 80 and over ; Bone Density Conservation Agents/therapeutic use ; Bone Density Conservation Agents/adverse effects

المؤلفون: Kumar S; Royal North Shore Hospital, Sydney, New South Wales, Australia shejil.kumar@health.nsw.gov.au.; The University of Sydney, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia., Beck BR; Griffith University, Gold Coast, Queensland, Australia., Nery L; Royal North Shore Hospital, Sydney, New South Wales, Australia., Byth K; Westmead Institute for Medical Research, Sydney, New South Wales, Australia., Elhindi J; Westmead Institute for Medical Research, Sydney, New South Wales, Australia., Wood C; Royal North Shore Hospital, Sydney, New South Wales, Australia., Fuller OK; Monash University, Melbourne, Victoria, Australia., Clifton-Bligh RJ; Royal North Shore Hospital, Sydney, New South Wales, Australia.; The University of Sydney, Sydney, New South Wales, Australia., Girgis CM; The University of Sydney, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia.

المصدر: BMJ open [BMJ Open] 2024 Aug 24; Vol. 14 (8), pp. e086708. Date of Electronic Publication: 2024 Aug 24.

نوع المنشور: Clinical Trial Protocol; Journal Article

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE

مواضيع طبية MeSH: Bone Density*/drug effects , Bone Diseases, Metabolic*/drug therapy , Osteoporosis, Postmenopausal*/drug therapy, Aged ; Female ; Humans ; Middle Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/therapeutic use ; Bone Density Conservation Agents/therapeutic use ; Bone Density Conservation Agents/administration & dosage ; Exercise Therapy/methods ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/physiopathology ; Quality of Life ; Randomized Controlled Trials as Topic ; Resistance Training/methods

المؤلفون: Wang H; Department of Orthopaedics, Peking University Third Hospital, Beijing, China., Huang J; Department of Orthopaedics, Peking University Third Hospital, Beijing, China., Tao L; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China., Liu D; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China. liudongyang@vip.sina.com., Song C; Department of Orthopaedics, Peking University Third Hospital, Beijing, China. schl@bjmu.edu.cn.

المصدر: Trials [Trials] 2024 Aug 13; Vol. 25 (1), pp. 534. Date of Electronic Publication: 2024 Aug 13.

نوع المنشور: Journal Article; Clinical Trial Protocol

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

مواضيع طبية MeSH: Osteoporosis, Postmenopausal*/drug therapy , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects , Bone Density Conservation Agents*/administration & dosage , Diphosphonates*/therapeutic use , Diphosphonates*/adverse effects , Diphosphonates*/administration & dosage , Randomized Controlled Trials as Topic* , Low Back Pain*/drug therapy , Imidazoles*/therapeutic use , Imidazoles*/adverse effects , Imidazoles*/administration & dosage, Humans ; Female ; Aged ; Treatment Outcome ; Middle Aged ; Pain Measurement ; Bone Density/drug effects ; Alendronate/therapeutic use ; Alendronate/adverse effects ; Alendronate/administration & dosage

المؤلفون: Schini M; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, S10 2TN, United Kingdom., Vilaca T; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, S10 2TN, United Kingdom., Lui LY; California Pacific Medical Center, Research Institute, San Francisco, 94158, CA, United States., Ewing SK; Department of Epidemiology & Biostatistics, University of California, San Francisco, 94158, CA, United States., Thompson A; Department of Epidemiology & Biostatistics, University of California, San Francisco, 94158, CA, United States., Vittinghoff E; Department of Epidemiology & Biostatistics, University of California, San Francisco, 94158, CA, United States., Bauer DC; Department of Epidemiology & Biostatistics, University of California, San Francisco, 94158, CA, United States.; Department of Medicine, University of California, San Francisco, 94158, CA, United States., Bouxsein ML; Department of Orthopedic Surgery, Harvard Medical School, Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Boston, 02215, MA, United States., Black DM; Department of Epidemiology & Biostatistics, University of California, San Francisco, 94158, CA, United States., Eastell R; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, S10 2TN, United Kingdom.

المصدر: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2024 Aug 05; Vol. 39 (7), pp. 867-876.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Bone and Mineral Research Country of Publication: England NLM ID: 8610640 Publication Model: Print Cited Medium: Internet ISSN: 1523-4681 (Electronic) Linking ISSN: 08840431 NLM ISO Abbreviation: J Bone Miner Res Subsets: MEDLINE

مواضيع طبية MeSH: Bone Density*/drug effects, Humans ; Female ; Male ; Aged ; Middle Aged ; Risk Factors ; Fractures, Bone/drug therapy ; Bone Density Conservation Agents/therapeutic use ; Bone Density Conservation Agents/pharmacology ; Randomized Controlled Trials as Topic ; Spinal Fractures/drug therapy ; Spinal Fractures/diagnostic imaging ; Osteoporosis/drug therapy

المؤلفون: Chen PJ; Department of Growth and Development, College of Dentistry, University of Nebraska Medical Center, Lincoln/Omaha, NE, USA. pchen@unmc.edu., Mehta S; Department of Orthodontics, School of Dentistry, Texas A&M University, Dallas, TX, USA., Dutra EH; Division of Orthodontics, School of Dental Medicine, UConn Health, Farmington, CT, USA., Yadav S; Department of Growth and Development, College of Dentistry, University of Nebraska Medical Center, Lincoln/Omaha, NE, USA.

المصدر: Progress in orthodontics [Prog Orthod] 2024 Jul 15; Vol. 25 (1), pp. 25. Date of Electronic Publication: 2024 Jul 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 100936353 Publication Model: Electronic Cited Medium: Internet ISSN: 2196-1042 (Electronic) Linking ISSN: 17237785 NLM ISO Abbreviation: Prog Orthod Subsets: MEDLINE

مواضيع طبية MeSH: Alendronate*/pharmacology , Alendronate*/therapeutic use , Osteogenesis Imperfecta*/drug therapy , Osteogenesis Imperfecta*/pathology , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/pharmacology , Temporomandibular Joint*/pathology , Temporomandibular Joint*/drug effects, Animals ; Mice ; Male ; Female ; Matrix Metalloproteinase 13/metabolism ; ADAMTS5 Protein ; Disease Models, Animal ; Bone Density/drug effects ; Proteoglycans

المصدر: The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2024 Jul 08; Vol. 66 (1706), pp. e112-e114. Date of Electronic Publication: 2024 Jul 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Medical Letter Country of Publication: United States NLM ID: 2985240R Publication Model: Electronic Cited Medium: Internet ISSN: 1523-2859 (Electronic) Linking ISSN: 0025732X NLM ISO Abbreviation: Med Lett Drugs Ther Subsets: MEDLINE

مواضيع طبية MeSH: Osteoporosis, Postmenopausal*/drug therapy , Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects, Humans ; Female ; Bone Density/drug effects

المصدر: The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2024 Jul 08; Vol. 66 (1706), pp. 105-112.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Medical Letter Country of Publication: United States NLM ID: 2985240R Publication Model: Print Cited Medium: Internet ISSN: 1523-2859 (Electronic) Linking ISSN: 0025732X NLM ISO Abbreviation: Med Lett Drugs Ther Subsets: MEDLINE

مواضيع طبية MeSH: Bone Density Conservation Agents*/therapeutic use , Bone Density Conservation Agents*/adverse effects , Bone Density Conservation Agents*/administration & dosage , Osteoporosis, Postmenopausal*/drug therapy, Female ; Humans ; Bone Density/drug effects ; Diphosphonates/therapeutic use ; Diphosphonates/adverse effects ; Diphosphonates/administration & dosage